Data Science Hub in Kenya: Innovating Health Equity

By Sumona Bose

February 25, 2024

Introduction

In a groundbreaking effort to improve health and care delivery in local communities, Aga Khan University (AKU) and the University of Michigan (U-M) have joined in partnership to establish a cutting-edge data science hub in Nairobi, Kenya. This collaborative initiative positions the power of artificial intelligence (AI) and machine learning (ML) to address health disparities and promote health equity.

Under the leadership of Joseph Kolars, director of the U-M Center for Global Health Equity, a delegation from Michigan recently visited AKU’s Nairobi campus to review the progress of their partnership. The meetings focused on the achievements since the signing of a memorandum of understanding (MOU) and provided updates on the Utilising Health Information for Meaningful Impact in East Africa through Data Science (UZIMA-DS) grant, which the institutions received two years ago.

A Collaborative Approach to Health Equity

The UZIMA-DS grant, amounting to $6.5 million, aims to establish a state-of-the-art data science hub that leverages AI, machine learning, and other emerging technologies to enhance health and care delivery in local communities. During the visit, project leads shared their progress and discussed the future of the initiative. This opportunity was a timely window to explore how both institutions can discuss challenges and find constructive routes to addressing them.

AI in Action: Looking at the Future of Healthcare

The collaboration between AKU and U-M extends beyond the UZIMA-DS grant. The visit also allowed for discussions on the new grant which supports pilot work for the Longitudinal Study of Health and Aging in Kenya (LOSHAK). This study aims to enrol thousands of Kenyan adults aged 45 and older, focusing on areas such as Alzheimer’s disease, mental health, the health and economic impacts of climate change and air pollution, and factors influencing late life economic wellbeing.

The success of this visit highlights the commitment of both institutions to advancing health equity through innovative research and collaboration. By leveraging the power of AI and machine learning, AKU and U-M are paving the way for transformative advancements in healthcare delivery, ultimately improving the lives of individuals and communities in Kenya and beyond.

Reference url

Recent Posts

National Health Insurance South Africa
    

Reassuring the Private Sector on National Health Insurance South Africa: A Path to Universal Coverage

🌍 How can South Africa achieve universal healthcare without sidelining private providers?

The National Health Insurance (NHI) represents a pivotal shift in South Africa’s commitment to offering equitable health coverage. Recent assurances from the Treasury highlight a desire to collaborate with the private sector, aiming for a hybrid approach that leverages the best of both worlds.

Curious about how this initiative could reshape the healthcare landscape? Jump into the full article for in-depth insights on the challenges, potential funding models, and the international lessons that can guide this transformative journey.

#SyenzaNews #HealthEconomics #HealthTech #HealthcarePolicy

MASLD CKD socioeconomic link
    

Exploring the MASLD CKD Socioeconomic Link

🌍 Are socioeconomic factors influencing your health more than you realise?

Our latest article looks into the intriguing link between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD), revealing significant geographical and socioeconomic correlations. Discover how understanding these relationships can inform public health strategies and improve health equity worldwide.

Dive into the findings and implications for health outcomes!

#SyenzaNews #HealthEconomics #globalhealth #HealthcareInnovation

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.